NK-92 ® CELLS - Brink Biologics

TO START A CELL LICENSING REQUEST – PLEASE FILL OUT REQUEST FORM

Next generation bioanalytical solutions

Our licensing process:

1

Fill out request form

2

Receive, review, and sign NDA

3

Review term sheet for license

4

Discuss details of license, finalize, sign and pay fees

5

Obtain cells under license

6

Receive Technical Support & Research Services

Neukopanel® Cell Request Form

for Proprietary Neukoplast® NK-92 Cells

Please complete form to initiate licensing process

Fill out my online form.

Taking you beyond the Brink of binding™
with our Killer Assays™.

THE NK-92® ASSAY COMPANY

Brink Biologics, Inc. (BBI) is a ImmunityBio, Inc. (NASDAQ: IBRX) affiliated biotechnology solutions company located in the prestigious Torrey Pines biotechnology science park in San Diego, CA.

KILLER CELLS - KILLER ASSAYS™

Natural Killer cell lines originating from a singular source, established in stable cultures under GLP & cGMP conditions and further modified into multiple panels of lines suitable for a range of laboratory testing applications.

Proprietary NEUKOPANEL® CELL LINES

A standardized panel of CD16 expressing NK-92® cell lines, provides for the first time the means to establish a consistent, robust and reliable assay for assessment of ADCC activity.

ADCC ASSAYS – ROUTINE HASSLE

Brink Biologics, Inc. holds the exclusive non-clinical rights to the NK-92®️ cell line and its CD16 expressing derivatives, all of which are uniquely and ideally suited for antibody-dependent cell-mediated cytotoxicity (ADCC) assays.

ROUTINE ASSAY

TIME CONSUMING AND A LACK OF OPTIONS

OUR SIMPLE SOLUTION

The exclusive global provider of THE NK-92® cell line (AND ITS VARIANTS) AND THE NEUKOPANEL™ testing services, NEUKOPANEL™ CELL PANELS, and sublicenses within the life sciences and device industry.

Highly published cell lines – over 200 publications.
Relevant Examples:
Schnueriger, A., et al. (2011). “Development of a quantitative, cell-line based assay to measure ADCC activity mediated by therapeutic antibodies.” Mol Immunol 48(12-13): 1512-1517.

Binyamin, L., et al. (2008). “Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy.” J Immunol 180(9): 6392-6401.

NK-92® cells are the only continuously growing human NK cell adapted to mass production
Brink Biologics created the NK-92® master cell bank (MCB).

EXCLUSIVE

NK-92® MCB has been accepted as clinical grade material by regulatory agencies across the world, including the US FDA, EMEA and Canada Health.

RECOGNIZED QUALITY

The sole holder of homogeneously pure NK-92® cell cultures with superb retention of phenotypic characteristics in more than 6 months of continuous culture.

PURE CELL LINE

Five Advantages of Neukopanel® Cell Lines:

For the first time the means to establish a consistent, robust and reliable assay for assessment of true ADCC function.



Cost & Time Savings



True Cytotoxicity



Ease of Use



Robust Assay



Eliminates Phenotypic Variability

Cost and time savings over common practice using donor-sourced (PBMC) NK cell isolation, expansion and maintenance in short term cultures
Eliminates phenotypic variability of donor-sourced NK cells as Neukopanel cell lines offer clonal consistency, purity and reliability as an assay reagent
Ease of use over donor-sourced NK cells and capable of long-term continuous cultures
Ability to generate a readout spectrum with the use of our homozygous high and low affinity CD16 expressing lines alongside our negative control line for assay robustness
True cytotoxicity rather than cell-binding readouts

Brink Biologics Announces License Agreement with Global Healthcare Company Fresenius Kabi SwissBioSim GmbH

Sep 10, 2020

SAN DIEGO, Calif., September 10, 2020 – Brink Biologics, Inc. (“Brink”), a NantKwest, Inc. (NASDAQ: NK) affiliate and exclusively-licensed distributor of NantKwest’s proprietary off-the-shelf NK-92® natural killer cells in certain fields, announces the licensing of...

Brink Biologics Announces Research License Agreement with Worcester Polytechnic Institute for Use of NantKwest’s NK-92® Cells

May 1, 2019

NK-92® Cell Based Bioanalytical Solutions are the Key to Optimizing R&D and Commercial Product Development Efforts for Monoclonal Antibodies, Bi-Specifics and Related Biological Products SAN DIEGO--May 1, 2019-- Brink Biologics, Inc., a NantKwest,...

NantKwest Announces New haNK Natural Killer Cell Patent Issuance Further Expanding Intellectual Property Estate

Apr 1, 2019

New haNK and T-haNK Based Natural Killer Cell Therapy Programs to Transition to Human Clinical Trials in 2019CULVER CITY, CA - April 1, 2019 - NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced...



Office

3530 John Hopkins Court
San Diego, CA 92121



Hours

8am to 5pm M-F



Call Us

Main: (858) 633-0300
Fax: (858) 380-1999

Email: info@brinkbiologics.com

‘Brink Biologics’, ‘Taking You Beyond the Brink of Binding’, ‘Neukopanel’, ‘Killer Assays’ and ‘laNK’ are trademarks or registered trademarks of Brink Biologics, Inc., ‘haNK’, 'Neukoplast', and ‘NK-92’ are registered trademarks of ImmunityBio, Inc.
The content of this website is protected by Title 17 of the U.S. Code and may not be reproduced in whole or in part by any means.